phase-1-formulation-support
IND submission timelines are tight, and formulation uncertainty causes costly delays. What if you could predict three months of stability testing in just three weeks? Discover how to accelerate your Phase 1 trials.
Menu
What if Three Months of Stability Testing Could Be Predicted in Three Weeks?
Understanding the Problem: The High Cost of Formulation Uncertainty
Action Plan: A Data-Driven Path to an IND-Ready Formulation. [11]
Quick Facts: The Impact of a Predictive Formulation Strategy. [12, 13]
Lead with Confidence
Literature
What if Three Months of Stability Testing Could Be Predicted in Three Weeks?
For Chemistry, Manufacturing, and Controls (CMC) and Drug Product (DP) leaders, the timeline from a promising molecule to a successful Investigational New Drug (IND) submission is a demanding process. You have optimized the molecule and scaled the drug substance. Now, the entire program depends on a stable, scalable, and regulatory-sound formulation. This step is where up to 60% of projects face many delays due to unexpected problems. Every failed stability run or unexpected aggregation issue can cost three months, delaying deadlines and putting financing at risk. [1]
Understanding the Problem: The High Cost of Formulation Uncertainty
You deal with high stakes and strict deadlines. The IND submission window is closing, and the pressure from your board to initiate Phase 1 trials is growing. An unstable formulation is not just a scientific problem; it is a direct threat to your clinical and business goals.
Common bottlenecks that can delay a Phase 1 timeline include:
Failed Stability Runs: A formulation that shows aggregation or degradation under accelerated conditions can cause many delays, requiring a complete redesign that wastes time and materials.
Regulatory Scrutiny: An incomplete or poorly justified CMC data package is a main reason for FDA questions or clinical holds. Regulators require strong data showing that your formulation is stable, and your chosen excipients are safe and understood. [2, 3]
Cold-Chain Dependence: Formulations requiring careful cold-chain handling add a lot of cost and risk. A single temperature excursion during shipping can ruin an entire clinical batch, causing estimated losses of $35 billion annually for the industry. [5, 6, 7, 8]
Tech Transfer & Scale-Up Surprises: A formulation developed in the lab may not work as expected during scale-up for GMP manufacturing. Issues with viscosity, filterability, or unexpected interactions with manufacturing surfaces can show up late, leading to expensive rework. [8]
These challenges are worse for complex biologics like viral vectors or antibody-drug conjugates (ADCs), where natural instability makes formulation design even more crucial. The traditional approach of trial-and-error screening is often too slow and uses too many materials to meet the tight timelines of early-phase development. [9, 10]
Action Plan: A Data-Driven Path to an IND-Ready Formulation. [11]
Instead of relying on repeated guessing, a systematic, data-driven approach can reduce risks in your formulation strategy and speed up your CMC timeline. By combining predictive modeling with fast analytics, you can gain confidence and control in your Phase 1 formulation support. The goal is to design a strong formulation from the start, following a Quality by Design (QbD) approach that meets regulatory expectations.
Quick Facts: The Impact of a Predictive Formulation Strategy. [12, 13]
Faster Timelines: Reduce formulation screening from months to weeks.
Save Materials: Use less expensive and limited drug substance with smaller, more focused experiments.
Reduced Risk: Find and fix potential stability problems like aggregation and degradation pathways before they delay your program.
Regulatory Confidence: Create a complete, IND-ready data package based on science.
Here is a clear, three-step plan to get a stable, scalable, and compliant formulation for your Phase 1 trial.
1. Predict Developability with AI-Guided Design
The first step is to go beyond traditional screening and use predictive analytics to find the best formulation options. Using advanced algorithms and a comprehensive database of excipient interactions, it is possible to predict how your specific molecule will act in hundreds of different buffer and excipient combinations. This computer screening quickly shows what won't work and points to a small, focused set of conditions to test in the lab. [15]
This approach allows for a smarter and more efficient experimental design. To learn more about this process, explore how to implement a data-driven approach to biologic formulation design. This method helps you choose the best buffers, salts, and stabilizers with a better chance of success, saving important time and resources. For biologics likely to have stability problems, understanding how to apply ML-guided excipient selection can make your strategy even better.
2. Optimize for Long-Term Stability and Reduce Cold-Chain Dependency
Phase 1 stability only needs to cover the trial's duration, but designing with long-term commercial viability in mind is a smart advantage. The goal is to create a formulation that is not only stable in the fridge (2-8°C) but also strong enough to withstand shipping excursions and, ideally, achieve room-temperature stability. [18]
This involves testing a selection of excipients known to stop specific degradation issues like oxidation, deamidation, and aggregation. Techniques such as differential scanning calorimetry (DSC) and dynamic light scattering (DLS) can check structural and colloidal stability under different stress conditions. [19, 20] For molecules with natural stability problems, lyophilization is a great solution. Investigating a liquid-to-lyo formulation conversion can make a very stable product that lasts longer, making logistics much simpler. Developing a lyophilized formulation for single-dose vials is a known way to keep the product intact from manufacturing to patient administration.
3. Deliver a Scalable, IND-Ready Data Package
The main goal of Phase 1 formulation support is to create a strong CMC package that meets FDA rules. This means more than just finding a main formulation. It needs a complete set of data that explains your choices and shows you control the manufacturing process. [21]
Your CMC package needs to include:
Forced Degradation Studies: Data showing how well your analytical methods show stability.
Excipient Justification: A clear reason for choosing each component and its concentration in the formulation.
Preliminary Stability Data: Real-time and accelerated stability data on a typical batch of your drug product.
Manufacturing Process Narrative: A description of the manufacturing process, showing its ability to consistently make a quality product. [23]
For bispecific antibodies, which have unique challenges, understanding how to select excipients for bsAb formulations is very important. Similarly, a closer look at how to develop stable liquid bsAb formulations can give the specific information needed for a successful IND submission.
Lead with Confidence
Your journey to Phase 1 doesn't have to be full of uncertainty and delays. By using a predictive, data-driven formulation strategy, you can speed up your CMC timeline, lower program risk, and move forward confidently.
Schedule a strategy call with our formulation experts to speed up CMC, reduce risk, and move forward confidently.
Accelerate Your CMC
IND-ready · De-risked · Scale-tested · Room-temp optimized · No guesswork
Literature
EuropeanCurrent time information in नागपूर डिव्हिजन, IN. Medicines Agency. (2014). Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials. EMA/CHMP/BWP/534898/2008 Rev. 2. [1]
Food and Drug Administration. (2022). IND Applications for Clinical Investigations: Chemistry, Manufacturing, and Control (CMC) Information. [15]
International Council for Harmonisation. (2009). ICH Harmonised Tripartite Guideline: Pharmaceutical Development Q8(R2). [12]
International Council for Harmonisation. (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2). [3]
International Council for Harmonisation. (1995). ICH Harmonised Tripartite Guideline: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products Q5C. [21]
Rathore, A. S. (2016). Quality by design for biologics. John Wiley & Sons. [23]
Singh, S. K., & Ittah, A. (2018). Challenges in Formulation and Delivery of Biologics. In Biologics and Biosimilars: A New Era in Drug Development. Springer. [26]
World Health Organization. (2021). The vaccine cold chain. [13]
Jiskoot, W., & Crommelin, D. J. A. (2020). Methods for structural analysis of protein pharmaceuticals. AAPS Press. [7]
Manning, M. C., Chou, D. K., Murphy, B. M., Patel, R. W., & Kamerzell, T. J. (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical research, 27(4), 544–575. [27]
